← Back to Search

Behavioural Intervention

Exoskeleton-Assisted Movement for Stroke

N/A
Recruiting
Led By Jose L Pons, Ph.D
Research Sponsored by Shirley Ryan AbilityLab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No history of a brain and/or skull lesion
Age from 18 to 80 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up for experiment b, change between baseline and through participant completion, an average of 3 months.
Awards & highlights

Summary

This trial will test whether the decoder can control the exoskeleton in real-time based on HD-EMG recordings from the participant's muscles with the aim of providing functional assistance.

Who is the study for?
This trial is for adults aged 18-80 with normal movement in their limbs, no brain/skull lesions, correctable hearing and vision. It includes stroke survivors who had a unilateral, supratentorial stroke over 6 months ago without other neurological disorders.
What is being tested?
The study tests a new controller for exoskeletons that uses muscle signals to predict movements. Participants will perform various muscle contractions and activities while wearing an exoskeleton that's guided by this technology.
What are the potential side effects?
Since the intervention involves physical activity with an exoskeleton based on muscle signals, potential side effects may include muscle fatigue or discomfort from the device.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have never had a brain or skull lesion.
Select...
I am between 18 and 80 years old.
Select...
My hearing and vision are normal or corrected to normal.
Select...
I do not have any conditions that cause unusual movements in my arms or legs.
Select...
I do not have any neurological disorders.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~for experiment b, change between baseline and through participant completion, an average of 3 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and for experiment b, change between baseline and through participant completion, an average of 3 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in 10WMT
Change in 6MWT
Change in Berg Balance Scale
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Healthy ParticipantsExperimental Treatment5 Interventions
The investigators will look at muscle activity of healthy participants from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).
Group II: Clinical ParticipantsExperimental Treatment5 Interventions
The investigators will look at muscle activity of participants post-stroke from eight lower limb muscles during functional tasks (e.g. single-joint movement, walking, squatting, cycling).

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
204 Previous Clinical Trials
17,759 Total Patients Enrolled
71 Trials studying Stroke
8,561 Patients Enrolled for Stroke
Jose L Pons, Ph.DPrincipal InvestigatorShirley Ryan AbilityLab
1 Previous Clinical Trials
1 Total Patients Enrolled

Media Library

Real-time Neuromuscular Control of Exoskeletons (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT04661891 — N/A
Stroke Research Study Groups: Healthy Participants, Clinical Participants
Stroke Clinical Trial 2023: Real-time Neuromuscular Control of Exoskeletons Highlights & Side Effects. Trial Name: NCT04661891 — N/A
Real-time Neuromuscular Control of Exoskeletons (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04661891 — N/A
~21 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top